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Objective: To identify risk factors for late recovery and failure after ambulatory
treatment of exacerbations of chronic bronchitis (CB) and chronic obstructive
pulmonary disease (COPD).
Methods: Observational, non-randomised study of risk factors carried out in 2001
and 2002 in Primary Care practices. Patients aged 40 or older diagnosed with an
exacerbation of CB or COPD of probable bacterial etiology were included in the study
and followed up for 10 days. Patients were treated with amoxicillin plus clavulanic
acid (co-amoxiclav) 500–125mg tds for 10 days, clarithromycin 500mg bd for 10 days
or moxifloxacin 400mg od for 5 days.
Results: Two hundred and fifty-two general practitioners participated, registering
1147 valid patients. The rate of failure at day 10 was 15.1% without significant
differences among the antibiotic treatments. Median time to recovery was 5 days.
Factors significantly associated with late recovery (45 days) on multivariate analysis
were: use of long-term oxygen (OR ¼ 1.96; 95%CI ¼ 1.35–2.85); use of short-acting
beta-2 agonists (OR ¼ 1.51; 1.17–1.92). The use of moxifloxacin had a ‘‘protective’’
effect against late recovery compared to co-amoxiclav (OR ¼ 0.34; 0.26–0.45) and
clarithromycin (OR ¼ 0.41; 0.31–2.85). Factors associated with therapeutic failure
were: previous hospitalisation (OR ¼ 1.61; 1.08–2.42); and 2 or more exacerbationsElsevier Ltd. All rights reserved.
ing in the EFEMAP study is included in the appendix. The EFEMAP study was funded by Bayer
4 93 2275549.
s (M. Miravitlles).
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M. Miravitlles et al.956the previous year (OR ¼ 1.51; 1.04–2.17); criteria of CB had a protective effect
against failure (OR ¼ 0.53; 0.35–0.79).
Conclusions: There are readily identifiable risk factors for ambulatory treatment
failure of exacerbations of CB and COPD. In addition, long-term oxygen therapy and
short-acting beta-2 agonists are associated with late recovery, and the use of
moxifloxacin compared with co-amoxiclav and clarithromycin is associated with
faster recovery of symptoms.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic pulmonary disease, particularly chronic
bronchitis (CB) and chronic obstructive pulmonary
disease (COPD), constitutes one of the principal
demands on health care in primary care. According
to recent studies, it is estimated that in Spain
up to 8–10% of the population over 40 years
of age may have COPD1,2 and, in men over 65
years of age, this figure may rise to 20%.2 The
course of both CB and COPD can be affected by
crises of worsening of the respiratory symptoms,
which are known as exacerbations. According to
reported findings, a high percentage of these
exacerbations, between 50% and 70%, are caused
by bacteria.3
Studies performed in the community have shown
that patients with COPD have a mean of two
exacerbations per year, 90% of which are treated
with antibiotics.4 However, the failure rate of an
exacerbation after ambulatory treatment may be
as high as 20–25%.5–7 Some recent guidelines have
pointed out that the ability to identify patients at
high risk for therapeutic failure should help to
guide decisions concerning hospital admission
and follow-up appointments.8 Therefore, studies
aimed at identifying risk factors for treatment
failure in real life conditions are required. In
addition, the speed of recovery of symptoms of
exacerbation is important in patients with chronic
bronchial disease. Milder patients may return to
work or normal activities earlier and more severe
patients may avoid respiratory failure if recovery of
symptoms is achieved in a short period of time.
Knowing the time course of symptoms and the risk
factors for late recovery may help physicians to
schedule follow-up visits and interpret the out-
comes of therapy. In a previous analysis of data
derived from this cohort, we evaluated the clinical
evolution of exacerbations under different anti-
biotic regimens.9 The aim of the present study was
to identify which variables of the patients and
treatment are significantly associated with an
increased risk of treatment failure or late recovery
of symptoms.Method
Patients
Patients elegible for participation in the EFEMAP
study (Estudio FarmacoEcono´mico de Moxifloxacino
en las Agudizaciones de la EPOC) had a clinical
diagnosis of exacerbation of CB and/or COPD of
probable bacterial aetiology and were aged 40
years or older. Diagnosis of an exacerbation of
probable bacterial aetiology was established when
the patient presented with a type I or type II
exacerbation as described below. Classification of
exacerbations followed the criteria described by
Anthonisen et al.10 increase in the usual level of
dyspnoea, increase in sputum volume, and/or
increase in the purulence of the sputum. Exacer-
bations presenting one of these symptoms were
classified as type III, those with two symptoms as
type II and those with all three symptoms as type
I.10 Patients with type III exacerbations were not
included in the study, since their probability of
bacterial infection is very low and usually do not
require antibiotic therapy.
To establish the diagnosis of CB, the patient
should refer a productive cough for at least 3
months a year for 2 consecutive years; for the
diagnosis of COPD, the observation of a non-
reversible airflow obstruction was required, char-
acterised on forced spirometry by an FEV1o80% of
the theoretical value and an FEV1/FVC ratio of
o70% in a stable phase.11 Patients with bronchial
asthma, cystic fibrosis, bronchiectasis, malignancy,
pneumonia and those patients who fulfilled criteria
for hospitalisation were excluded.Study design
Full details of the study design have been published
elsewhere.9,12 This was an observational study of a
population of patients with exacerbated CB or
COPD being followed in primary care centres
distributed throughout Spain.
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Variables associated with acute exacerbations of CB and COPD 957After diagnosis of the exacerbation, the partici-
pating investigators were free to prescribe any of
the three following options of antibiotic treatment:
association of co-amoxiclav 500mg/8 h for 10 days,
moxifloxacin 400mg/day for 5 days, or clarithro-
mycin 500mg/12 h for 10 days, in accordance with
the current guidelines.13 A medical appointment
was made for all the patients 10 days after the first
visit, when they were asked about the number of
days which had passed from starting treatment
until resolution of the symptoms of exacerbation.
The first outcome of the study was time to the
resolution of symptoms. Fast recovery was defined
as the resolution of symptoms in days below the
median duration of symptoms for the whole group.
Treatment failure was defined as failure to return
to baseline before 10 days or the requirement of
new treatments or medications during the first 10
days for persistence or aggravation of symptoms.
This study was notified to the Spanish Health
Authorities and complied with Spanish legislation
on observational studies. The medication pre-
scribed was that recommended in the current
Spanish guidelines13 and all data in the database
were coded to maintain confidentiality.Data collection
All the data generated were collected on a form in
electronic format designed specifically for the
study. This form included information on demo-
graphic variables, respiratory risk factors, co-
morbidity, number of previous exacerbations de-
fined as episodes of aggravation of respiratory
symptoms requiring treatment with antibiotics,
corticosteroids or both and which were documen-
ted in clinical records, characteristics of the
patient’s respiratory disease, degree of dyspnoea
(0, no dyspnoea; I, dyspnoea when climbing two
floors; II, dyspnoea when climbing one floor; III,
dyspnoea when walking on flat ground; IV, resting
dyspnoea), usual medication, characteristics of the
exacerbation and treatment administered. The
form was loaded into a portable personal handheld
computer (PCA), Hewlett Packard Jornada 545
(Colour Pocket PC), using a 32 bit processor, 16MB
of RAM and 16MB of ROM. Data transmission to a
unified database was carried out on-line by tele-
phone connection via a CompactModem modem for
Pocket PCs at 56 K and 3.3 V. To ensure confidenti-
ality, the data transferred contained no informa-
tion which could identify the participating
individuals. The information was included in a
single database located on the server and adminis-
tered by the centre for data recording and analysis(Biomedical Systems Group, S.A. Barcelona). A
pilot study was performed to test the correct
functioning of the system and the results of this
study were published recently.12Statistical analysis
The association of categorical independent vari-
ables with failures was assessed by the chi-square
test, and the significance of continuous variables
was assessed with the Student’s t-test and Wilcox-
on’s Rank Sum Tests. A regression model was
constructed to identify variables independently
and significantly associated with treatment failure.
The model was constructed using a randomly
selected subsample of 90% of the subjects inclu-
ded—developmental model. The model obtained
was tested with data derived from the remaining
10% of the total population—validation sample.
The developmental and validation samples were
created by assigning each patient a random number
between 0 and 1. Patients with a random number of
0.90 or lower formed the developmental sample
and the remaining patients formed the validation
sample.
We wanted our model to accurately reflect the
failure experience of the patient sample while
containing the minimum number of variables
necessary to calibrate and discriminate well in
the developmental and validation samples. Only
clearly definable and reliably obtained terms were
included and the use of laboratory values, radi-
ological examinations and measurements, which
cannot be performed as part of routine patient
care, were avoided. Candidate variables included
in the model were: age, sex, smoking habits (active
smoker vs. non- or ex-smoker), years of evolution
of the disease, presence or absence of chronic
bronchitis, and co-morbidity coded as ‘‘0 ¼ no,
1 ¼ yes’’ for any of the following: ischemic heart
disease, diabetes mellitus or hypertension, chosen
by presenting a prevalence of 5% or greater of the
study population, severity of the underlying disease
quantified by the degree of dyspnoea, number of
exacerbations the previous year, severity of the
exacerbation based on classification as types I or II,
and treatment with oral steroids, inhaled short-
acting beta-2 agonists, inhaled long-acting beta-2
agonists, anticholinergics, long-term oxygen ther-
apy, inhaled corticosteroids, and antibiotics (moxi-
floxacin, clarithromycin or co-amoxiclav). Lung
function parameters were not included in the
model since only 54% of the population had
spirometric evaluation performed.
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variables independently and significantly associated
with the speed of recovery. For this model, the
population was divided into two groups, the group
with a fast resolution of symptoms (equal to or less
than 5 days) and the group with slow resolution of
symptoms (6 days or longer). A cut-off point of 5
days was chosen, since 5 days was the median time
to recovery for the whole group. The same
independent variables were included in the model.
Variables were eligible for entry into a multiple
logistic regression model if they were significantly
associated with failures at a P-value of less than
0.10 and at least 5% of the population exhibited
that factor. Correlations among the regression
coefficients were used to screen for multicollinear-
ity.14 Absolute values of r greater than 0.7 were
considered significant. The k statistic was used to
assess inter-rater reliability of variables. Estimated
coefficients and their SE’s were calculated using the
method of maximum likelihood. Variables were
eliminated from the model one at a time based on
likelihood ratio tests.
When all statistically non-significant ðP40:05Þ
variables had been eliminated from the multi-
variate model, calibration was assessed using the
Hosmer–Lemeshow goodness-of-fit test.15 This test
evaluates the degree of correspondence between a
model’s estimated probability of failure and the
actual failure rate of patients over groups spanning
the entire range of probabilities.
Discrimination was assessed using the area under
the receiver operating characteristic (ROC) curve16
to evaluate how well the model-distinguished
patients who failed from patients who did not.
The statistic represents, for all possible pairs of
patients, the proportion in which the patient who
failed had a higher probability of relapse than the
patient who did not.
Modeling for fast recovery of exacerbation, i.e.
in 5 days or less, followed the same process as the
modeling for failure.
All the data were analysed using the SAS 6.04
statistical package (SAS Institute, Cary, NC, USA).Results
Study population
A total of 252 primary care physicians participated
in the study. Information was received on 1656
patients, representing a mean of 6.6 patients per
investigator. Two hundred patients were excluded
from the study as they did not fulfil the inclusioncriteria, they fulfilled one or more of the exclusion
criteria or their follow-up data were incomplete. In
addition, 309 exacerbations were type III and were
excluded since they did not fulfill the criteria for
probable bacterial etiology. This left 1147 patients
valid for the final analysis. A total of 630 patients
(55%) had a diagnosis of COPD confirmed by
spirometry.
Most of the patients were men (81%) and the
mean age of the population was of 68.7 years (SD:
9.4). Of the patients with spirometry, the mean
FEV1 was of 51.4% (SD: 14%), signifying a moderate
alteration of pulmonary function. The mean num-
ber of exacerbations during the previous year was
2.4 (SD: 2.2) and only 4.8% of the patients had no
exacerbation during the previous year.
Globally, 25.6% of the exacerbations were classi-
fied as type I and 74.4% as type II. Patients with a
type I exacerbation had a significantly lower FVC
ðP ¼ 0:012Þ and a tendency towards a lower FEV1. In
addition, patients with type I exacerbations had
more frequent exacerbations in the past, with
77.5% experiencing two or more, compared with
70.5% of the patients who presented a type II
exacerbation ðP ¼ 0:022Þ (Table 1).Treatment and course of the exacerbations
The antibiotic treatment administered was co-
amoxiclav in 358 cases (31%), moxifloxacin in 482
(41%) and clarithromycin in 324 (28%). No signifi-
cant differences were found in the characteristics of
the patients and the severity of exacerbations
among the treatment groups (Table 2). Oral corti-
costeroids were prescribed to 24.6% of exacerba-
tions without differences among groups. The clinical
characteristics of the patients and the comparion of
the different variables between patients in whom
the exacerbation resolved and those with treatment
failure are presented in Table 3.
A total of 173 (15.1%) patients had treatment
failure and they were patients with a more severe
baseline pulmonary disease, demonstrated by an
increased degree of baseline dyspnoea ðP ¼ 0:002Þ:
They also had more frequent previous admissions
for an exacerbation ðP ¼ 0:004Þ and a non-signifi-
cant trend towards more frequent exacerbations in
the past year ðP ¼ 0:07Þ: In contrast, in patients
who failed symptoms of CB were less frequent (71%
vs. 82%, Po0:001Þ:
Regarding treatment, failure was significantly
more frequent in patients receiving inhaled
corticosteroids (71.6% vs. 61.1%; P ¼ 0:009Þ: No
significant differences were found in failure rates
among the different antibiotic options ðP ¼ 0:19Þ:
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Table 1 Demographic and clinical characteristics of patients with CB and/or COPD and type I or II
exacerbations.
Variables Type I (n ¼ 294) Type II (n ¼ 853) P-value
Sex, men 80.3% 81.2% 0.71
Age, years 68.5 (9.69) 68.8 (9.3) 0.73
Active smoker 21.8% 23.5% 0.55
Pack-years 36.4 (22.7) 37.3 (23.9) 0.80
Years of evolution 12.6 (8.2) 12.4 (7.8) 0.89
Comorbidity 56.1% 51.9% 0.20
CB 82.3% 80.3% 0.45
Baseline dyspnea
Degree 0 or 1 49.5% 47.0% 0.71
Degree 2 34.8% 37.5%
Degree 3 or 4 15.7% 15.5%
Lung function ðn ¼ 630Þ
FVC (ml) 2469 (893) 2624 (879) 0.012
FVC (%) 67.2 (15.3) 68.2 (16.6) 0.43
FEV1 (ml) 1474 (632) 1525 (643) 0.29
FEV1 (%) 51.9 (14.2) 51.2 (13.9) 0.48
Exacerbations previous year
0 or 1 22.5% 29.5% 0.022
2 or more 77.5% 70.5%
Admission previous year 0.3 (0.7) 0.3 (0.7) 0.43
Antibiotic prescribed
Moxifloxacin 42.5% 40.8% 0.85
Co-amoxiclav 30.6% 30.9%
Clarithromycin 26.8% 28.2%
Failure rate 16.4% 14.2% 0.35
Variables associated with acute exacerbations of CB and COPD 959Median time to resolution of symptoms was 5
days and 659 (57%) patients recovered before or at
5 days. Factors significantly associated with faster
recovery were a younger age ðP ¼ 0:016Þ and
lower number of previous admissions ðP ¼ 0:044Þ
(Table 4). Patients treated with short-acting beta-2
agonists had a higher rate of late recovery ðP ¼
0:008Þ; as did patients receiving long-term oxygen
therapy ðP ¼ 0:001Þ: A 70.3% of patients treated
with moxifloxacin recovered in 5 days or less
compared with 44.4% with amoxi-clav or 49.7%
with clarithromycin ðPo0:0001Þ:Results of the multivariate models for failure
and fast recovery
Table 5 shows the results of the multivariate
analysis of factors independently and significantly
associated with failure. Hospitalisation for an
exacerbation the previous year was significantly
associated with failure. Similarly, frequent exacer-bations the previous year were also significantly
associated with failure. In contrast, patients with
criteria of CB had a reduced risk of failure
(OR ¼ 0.53; 95% CI ¼ 0.35–0.79). The model was
well calibrated, as demonstrated by a P value of
0.99 in the Hosmer–Lemeshow test, and showed a
fair discrimination (c statistic or area under the
ROC curve 0.62).
In contrast to the previous model, only variables
related to treatment were significantly associated
with slow recovery. The use of long-term oxygen
was associated with a prolonged duration of
symptoms, as well as the use of short-acting beta-
2 agonists. The use of moxifloxacin compared to
amoxi-clav was a ‘‘protective’’ factor for slow
recovery (OR ¼ 0.34; 95% CI ¼ 0.26–0.45). Similar
results were observed comparing moxifloxacin with
clarithromycin (OR ¼ 0.41; 95% CI ¼ 0.31–0.55),
(Table 5). The model also showed a good calibration
(Hosmer-Lemeshow test, P ¼ 0:68) and fair discri-
mination (c statistic or area under the ROC curve
0.73).
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Table 2 Demographics of study patients by treatment group ðn ¼ 1164Þ:
All Moxilfoxacin
ðn ¼ 482Þ
Co-amoxiclav
ðn ¼ 358Þ
Clarithromycin
ðn ¼ 324Þ
P-value
Patient’s characteristics
Age (years) 68.7 (9.4) 69.2 (10.1) 68.6 (10) 68.5 (9.9) 0.82
Males (%) 81 82 80 80 0.87
Years of evolution of CB/COPD 13 (8) 13 (9) 11 (7) 13 (9) 0.67
More than 2 comorbidities (%) 27 25 25 28 0.43
Smokers and exsmokers (%) 81 81 80 78 0.41
Pack-years 43 (28) 43 (28) 43 (26) 44 (25) 0.67
Pulmonary function tests
ðn ¼ 630Þ
2497 (872) 2532 (820) 2506 (843) 2572 (833) 0.52
FVC (ml) 68 (16) 68 (17) 67 (16) 68 (16) 0.94
FVC (%) 1497 (653) 1490 (644) 1488 (639) 1501 (630) 0.59
FEV1 (ml) 51 (14) 51 (16) 51 (13) 51 (14) 0.95
FEV1 (%) 58 (13) 57 (14) 59 (15) 58 (14) 0.43
FEV1/FVC
During year prior to enrollment,
number of exacerbations
2.4 (2.2) 2.5 (1.6) 2.5 (1.5) 2.3 (1.8) 0.28
Characteristics of exacerbations
Anthonisen type I (%) 26.6 27.8 26.2 25.6 0.77
Treatment with oral steroids (%) 24.6 26.5 23 23.5 0.45
Data expressed as mean (standard deviation) unless otherwise specified. P-values with respect to the results of the comparison
between the three groups, Kruskal–Wallis test and chi-squared test when appropriate.
M. Miravitlles et al.960Discussion
The results of the present study indicate that the
use of long-term oxygen therapy and inhaled short-
acting beta-2 agonists are significantly associated
with a prolonged time to recovery from exacerba-
tions of CB/COPD. Although no significant differ-
ences were observed in the rate of treatment
failure with the different antibiotics prescribed in
the study, the use of moxifloxacin was associated
with a faster recovery compared to both, amoxi-
clav and clarithromycin. The treatment failure rate
at day 10 was 15.1% and patients who had a hospital
admission or two or more exacerbations the
previous year were at increased risk of failure. In
contrast, patients with criteria of CB were less
likely to fail after treatment of an exacerbation
compared with patients with emphysema.
In a previous study using data derived from this
cohort, we observed that patients treated with
moxifloxacin had a higher rate of cure at days 3 and
5 after initiating treatment for the exacerbation.
However, cure rates at day 10 did not significantly
differ for the different antibiotic options.9 In the
present study, we extended our analysis to identify
risk factors for slow recovery among the character-
istics of the patients, the severity of the exacer-
bation and the treatment prescribed for thebaseline bronchial disease and the exacerbations.
It is important for the patients to recover as quickly
as possible from their respiratory symptoms, thus
avoiding repeated visits to the doctor, symptomatic
medication, and even the use of a further course of
antibiotics or substitution of the antibiotic when a
lack of efficacy is suspected. Furthermore, there
are major economic implications, since early
recovery facilitates earlier return to work or usual
activities. Comparative results should be inter-
preted with caution, since this study is neither
experimental nor randomised and is, therefore,
subject to a possible selection bias in favour of one
treatment or another. Nonetheless, the participa-
tion of 252 investigators and the inclusion of more
than one thousand patients makes it unlikely for
the same bias to be systematically repeated in a
significant number of cases. Furthermore, the three
patient groups analysed were perfectly balanced in
all their demographic, clinical and functional
characteristics, as well as in the severity of the
exacerbations.9 Another argument in favour of the
similarity of the three groups is that the cure rates
achieved at 10 days did not significantly differ,
making selection bias very unlikely.
The prolonged time to recovery in patients
receiving long-term oxygen therapy is not
surprising, since this is a well-known marker of
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Table 3 Demographic and clinical characteristics of patients with CB and/or COPD and type I or II exacerbations
according to the outcome of the exacerbation.
Variables All (1147) Cure (974) Relapse (173) P-value
Sex, men 81.0% 80.8% 82.1% 0.69
Age, years 68.7 (9.3) 68.8 (9.2) 69.4 (9.5) 0.50
Active smoker 23.5% 22% 23.7% 0.61
Pack-years 36.9 (23.7) 37.2 (23.7) 36 (24) 0.79
Years of evolution 12.4 (7.8) 12.4 (8) 12.5 (6.5) 0.85
Comorbidity 54.2% 53.5% 58.1% 0.27
CB 80.5% 82.1% 71.1% o0.001
Baseline dyspnoea
Degree 0 or 1 47.4% 88.1% 11.9% 0.002
Degree 2 37.2% 85.8% 14.2%
Degree 3 or 4 15.4% 77% 23%
Lung function ðn ¼ 630Þ
FVC (ml) 2573 (785) 2590 (864) 2557 (889) 0.23
FVC (%) 68.3 (15.7) 69.1 (16.3) 68.4 (17.2) 0.46
FEV1 (ml) 1511 (618) 1521 (593) 1480 (747) 0.11
FEV1 (%) 52.0 (13.3) 52.2 (13.5) 49.4 (13) 0.54
Exacerbations previous year
0 or 1 27.8% 88.2% 11.8% 0.076
2 or more 72.2% 84% 16%
Admission previous year 0.31 (0.6) 0.28 (0.67) 0.49 (0.85) 0.004
Treatment
Short-acting beta-2 67.3% 66.3% 71.2% 0.21
Long-acting beta-2 69.5% 69.2% 75.1% 0.12
Ipratropium bromide 61.0% 59.8% 65.9% 0.13
Inhaled steroids 62.5% 61.1% 71.6% 0.009
Long-term oxygen 11.2% 10.5% 15.5% 0.057
Treatment of exacerbation
Moxifloxacin 41.3% 87.1% 12.9% 0.19
Co-amoxiclav 30.9% 83.9% 16.1%
Clarithromycin 27.8% 82.8% 17.2%
Oral steroids 24.6% 24% 26.5% 0.41
Variables associated with acute exacerbations of CB and COPD 961severity.6,17 However, the association between the
use of short-acting beta-2 agonists and longer
duration of symptoms is a new finding. It can be
hypothesized that the use of short-acting beta-2
agonists for rapid relief of dyspnoea by some
patients may substitute the use of more active
drugs such as oral corticosteroids or long-acting
bronchodilators. This effect has been demon-
strated in asthma. Patients using short-acting
beta-2 agonists instead of inhaled or oral corticos-
teroids during an exacerbation have a poorer
prognosis.18
In the present study, only exacerbations with a
high probability of bacterial aetiology, defined by
fulfilling the criteria for types I or II exacerbations10
were included. There were no significant differ-
ences in the outcomes for both types of exacerba-tions. Only the number of previous exacerbations
was different in both groups, with patients with a
type I exacerbation being more likely to have had
more frequent exacerbations in the past. This is in
agreement with the study by Donaldson et al.19
that showed that as the number of exacerbations
increase, their severity also increases.
The observed failure rate of 15.1% at day 10 is in
accordance with other studies performed in the
community. In a previous study by our group, a
failure rate of 21% at 30 days was demonstrated in a
population of 2414 exacerbated patients.7 In this
latter study, the presence of cardiac comorbidity,
an increased severity of the baseline respiratory
disease and the increased number of previous
exacerbations were risk factors for therapeutic
failure.7 Other published studies have reported
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Table 4 Demographic and clinical characteristics of patients with CB and/or COPD and type I or II exacerbations
according to the time to recovery from the symptoms of exacerbation.
Variables Fast recovery (o5
days) ðn ¼ 659Þ
Slow recovery (45
days) ðn ¼ 505Þ
P-value
Sex, men 81.9% 79.8% 0.36
Age, years 68 (9.8) 69.6 (8.7) 0.016
Active smoker 24.6% 21.4% 0.21
Pack-years 36.7 (24.1) 37.2 (23.2) 0.67
Years of evolution 12.1 (7.8) 12.8 (7.9) 0.13
Comorbidity 54.6% 54.5% 0.96
CB 80.9% 80.4% 0.84
Baseline dyspnea
Degree 0 or 1 58.4% 41.6% 0.09
Degree 2 52.2% 47.8%
Degree 3 or 4 50.9% 49.1%
Lung function ðn ¼ 630Þ
FVC (ml) 2581 (891) 2570 (881) 0.84
FVC (%) 67.5 (16.2) 68.6 (16) 0.12
FEV1 (ml) 1516 (653) 1499 (620) 0.96
FEV1 (%) 50.6 (14.1) 52.4 (13.8) 0.053
Exacerbations previous year
0 or 1 60.9% 39.1% 0.06
2 or more 54.8% 45.2%
Admission previous year 0.28 (0.7) 0.36 (0.61) 0.044
Treatment
Short-acting beta-2 64.1% 71.4% 0.008
Long-acting beta-2 68.6% 70.6% 0.44
Ipratropium bromide 59.4% 63.0% 0.22
Inhaled steroids 61.6% 63.6% 0.47
Long-term oxygen 8.5% 14.4% 0.001
Anthonisen’s type
Type I 55.1% 44.9% 0.58
Type II 57.0% 43.0%
Treatment of exacerbation
Moxifloxacin 70.3% 29.7% o.0001
Co-amoxiclav 44.4% 55.6%
Clarithromycin 49.7% 50.3%
Oral steroids 19.7% 29.8% 0.18
M. Miravitlles et al.962failure rates between 10% and 26%.5–7,10 Our results
consistently show that the increased number of
previous exacerbations and admissions was asso-
ciated with higher risk of failure. In addition, the
presence of symptoms of CB was associated with a
decreased risk of failure. It is possible that patients
with chronic mucus hypersecretion are more prone
to develop exacerbations that may be milder,20 in
contrast with patients with emphysema who may
develop respiratory failure more frequently during
the course of an exacerbation. Other risk factors
for failure proposed, such as older age and more
severe impairment in lung function were not
observed in the present study. A plausible explana-tion is the relative uniformity of the population
sample due to its selection from primary care
centers, which prevents the inclusion of significant
numbers of elderly patients. In addition, lung
function could not be included in the model,
because this information was lacking in a significant
number of individuals.
In summary, ambulatory treatment of exacerba-
tions fails in 15.1% of patients with exacerbations
of CB/COPD. Patients with the emphysematous
form of the respiratory disease and those with
frequent exacerbations or admissions are at in-
creased risk of failure. The mean duration of
symptoms of exacerbation is 5 days. Patients
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Table 5 Variables in the model for failure and
late recovery.
Variables Estimated
adjusted
OR
95% CI
(a) Variables in the model for failure
Previous hospitalization 1.61 1.08–2.42
Two or more
exacerbations previous
year
1.51 1.04–2.17
CB 0.53 0.35–0.79
(b) Variables in the model for late recovery (longer
than 5 days)y
Long-term oxygen 1.96 1.35–2.85
Short-acting beta-2
agonists
1.51 1.17–1.92
Moxifloxacin vs. amoxi/
clav
0.34 0.26–0.45
Moxifloxacin vs.
clarithromycin
0.41 0.31–0.55
Hosmer–Lemeshow goodness-of-fit test, P ¼ 0:99: ROC
area under the curve 0.62.
yHosmer–Lemeshow goodness-of-fit test, P ¼ 0:68: ROC
area under the curve 0.73.
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beta-2 agonists presented an increased risk of
prolonged exacerbations. Treatment with
moxifloxacin was associated with shorter duration
of symptoms compared to co-amoxiclav and
clarithromycin.Appendix
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